Stay updated with breaking news from Radcom. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com assumed coverage on shares of RADCOM (NASDAQ:RDCM – Free Report) in a research note issued to investors on Sunday. The firm issued a buy rating on the technology company’s stock. RADCOM Trading Up 0.7 % NASDAQ:RDCM opened at $8.43 on Friday. The firm has a market cap of $124.26 million, a PE ratio of […]
RADCOM Ltd. (NASDAQ:RDCM – Get Free Report) was the target of a significant drop in short interest in September. As of September 30th, there was short interest totalling 11,300 shares, a drop of 26.1% from the September 15th total of 15,300 shares. Based on an average daily volume of 7,900 shares, the days-to-cover ratio is […]
StockNews.com assumed coverage on shares of RADCOM (NASDAQ:RDCM – Free Report) in a research report report published on Saturday morning. The brokerage issued a buy rating on the technology company’s stock. RADCOM Stock Performance Shares of NASDAQ:RDCM opened at $8.21 on Friday. RADCOM has a 52-week low of $8.21 and a 52-week high of $11.50. […]
StockNews.com initiated coverage on shares of Dime Community Bancshares (NASDAQ:DCOM – Free Report) in a research report report published on Thursday. The brokerage issued a hold rating on the savings and loans company’s stock. Separately, Raymond James lifted their target price on Dime Community Bancshares from $23.00 to $27.00 and gave the stock an outperform […]
The dark cloud of what the U.S. FDA called potential “systemic bias” rained on Amgen Inc.’s bid for full approval of Lumakras (sotorasib), a KRAS-G12C inhibitor that was granted accelerated approval in May 2021 for locally advanced or metastatic non-small-cell lung cancer after at least one systemic therapy.